Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR2 | P21452 | 2/20 | 0.47 |
| ▸ | CDK4 | P11802 | 14/20 | 0.44 |
| ▸ | CCND1 | P24385 | 14/20 | 0.44 |
| ▸ | CDK2 | P24941 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1972531 | 0.93 | TACR2 (0.46) | TACR2CDK4CCND1CDK2HDAC1 | |
| SCHEMBL2404998 | 0.90 | MPO (0.43) | CDK4CCND1 | |
| SCHEMBL1966005 | 0.90 | CDK4 (0.50) | TACR2CDK4CCND1CDK2MEN1 | |
| SCHEMBL1974827 | 0.90 | TACR2 (0.49) | TACR2CDK4CCND1CDK2MEN1 | |
| SCHEMBL1969885 | 0.89 | TACR2 (0.51) | TACR2CDK4CCND1CDK2HDAC1 | |
| SCHEMBL1969807 | 0.88 | CDK4 (0.52) | TACR2CDK4CCND1CDK2HDAC1 | |
| SCHEMBL1972085 | 0.87 | TACR2 (0.46) | TACR2CDK4CCND1CDK2HDAC1 | |
| SCHEMBL1968745 | 0.86 | CDK4 (0.52) | TACR2CDK4CCND1CDK2MEN1 | |
| SCHEMBL1967482 | 0.86 | TACR2 (0.48) | TACR2CDK4CCND1CDK2MEN1 | |
| SCHEMBL1971216 | 0.84 | CDK4 (0.43) | TACR2CDK4CCND1CDK2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-09-01 | — | — | US | claimed |
| EP-2334643-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | Actelion Pharmaceuticals Ltd. (CH) | 2011-06-22 | — | — | EP | claimed |
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-09-01 | — | — | US | disclosed |
| EP-2334643-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | Actelion Pharmaceuticals Ltd. (CH) | 2011-06-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | HCRTR2, HCRTR1, HRH3 | TACR2 90/4885CDK4 3031/4885CCND1 3178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.